Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.2400
-0.0089 (-3.58%)
At close: Jul 16, 2026, 4:00 PM EDT
0.2419
+0.0019 (0.79%)
Pre-market: Jul 17, 2026, 9:01 AM EDT
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Vistagen Therapeutics stock have an average target of $1.00, which predicts a 316.67% increase from the current stock price of 0.24.
Price Target: $1.00 (+316.67%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Vistagen Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $1 | Hold | Maintains | $1 | +316.67% | Jul 6, 2026 |
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jul 1, 2026 |
Financial Forecast
Revenue This Year
633.33K
from 1.27M
Decreased by -50.09%
Revenue Next Year
n/a
from 633.33K
Decreased by -100.00%
EPS This Year
-1.48
from -1.83
EPS Next Year
-1.54
from -1.48
EPS and Forward PE are based on non-GAAP adjusted numbers.